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Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dys-
trophin gene that result in the absence of functional protein. Antisense-mediated exon skipping is one of
the most promising approaches for the treatment of DMD and recent clinical trials have demonstrated encour-
aging results. However, antisense oligonucleotide-mediated exon skipping for DMD still faces major hurdles
such as extremely low efﬁcacy in the cardiac muscle, poor cellular uptake and relatively rapid clearance from
circulation, which means that repeated administrations are required to achieve some therapeutic efﬁcacy. To
overcome these limitations, we previously proposed the use of small nuclear RNAs (snRNAs), especially
U7snRNA to shuttle the antisense sequences after vectorization into adeno-associated virus (AAV) vectors.
In this study, we report for the ﬁrst time the efﬁciency of the AAV-mediated exon skipping approach in the
utrophin/dystrophin double-knockout (dKO) mouse which is a very severe and progressive mouse model of
DMD. Following a single intravenous injection of scAAV9-U7ex23 in dKO mice, near-normal levels of dystroph-
in expression were restored in all muscles examined, including the heart. This resulted in a considerable im-
provement of their muscle function and dystrophic pathology as well as a remarkable extension of the dKO
mice lifespan. These ﬁndings suggest great potential for AAV-U7 in systemic treatment of the DMD phenotype.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe muscle-
wasting disorder affecting 1:3500 live male births, caused by
mutations in the dystrophin gene. The majority of mutations
disrupttheopenreadingframe,resultingintheabsenceofafunc-
tionaldystrophinproteinatthesarcolemmaofmuscleﬁbres.The
related allelic disorder Becker muscular dystrophy (BMD) is
caused by mutations that create shortened but in-frame tran-
scripts with production of partially functional dystrophin,
leading to a milder phenotype (1). One of the most promising
therapeutic strategy for DMD aims to convert an out-of-frame
mutation into an in-frame mutation, which would give rise to
internally deleted, but still functional dystrophin (1,2). This
can be achieved using antisense oligonucleotides (AOs) that
interfere with splice sites or regulatory elements within the
exon and thus induce the skipping of speciﬁc exons at the
pre-mRNA level (3,4). The applicability of AO therapy has
now been demonstrated in Phase I/II clinical trials with two dif-
ferent chemistries of AOs targeting the human dystrophin exon
51 in DMD patients (5,6). More recently, the systemic treatment
of DMD patients with AOs was reported to induce dose-
dependent exon-skipping efﬁcacy leading to detectable
amounts of dystrophin protein in skeletal muscles of patients
treated with 2 mg or more per kilogram (7,8). These preliminary
resultsappearpromisingandraiseexpectationstoahighlevelfor
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especially regarding the personalized medicine nature of the
strategy and the challenging delivery to all affected tissues in
DMD (9). Both chemistries used in clinical trials, 2′-O-methyl
phosphorothioate (2OMePS) and phosphorodiamidate morpho-
lino oligomers (PMO), are still limited by the poor cellular
uptake and relatively rapid clearance from circulation, which
means that repeated administrations are necessary to achieve
some therapeutic efﬁcacy. One way of circumventing this is to
deliver the antisense sequence using viral vectors. We and
others have previously demonstrated that small nuclear RNA
(snRNA) such as U1 and U7snRNA could induce efﬁcient
exon-skipping in vitro and in vivo when appropriately modiﬁed
with speciﬁc antisense sequences (10,11). The antisense se-
quence embedded into an snRNP particle is protected from deg-
radation and accumulates in the nucleus where splicing occurs.
When introduced into adeno-associated virus (AAV) vectors,
these snRNAs can induce long-term restoration of dystrophin
which represents a strong advantage of this approach over syn-
thetic AOs by eliminating the need for repeated injections.
A second hurdle with the systemic administration of AOs is
the high variability in exon-skipping efﬁciency among muscle
types. Data collected from mouse and dog studies have shown
that some muscles respond better than others (12–14). Even
withinthemostresponsivemuscles,dystrophinwasnotuniform-
ly expressed, with patches of both dystrophin-positive ﬁbres and
dystrophin-negative ﬁbres observed. Moreover, both 2OMePS
and PMO AOs have shown very little efﬁcacy in the heart
(12,15), which is currently a major challenge to the therapeutic
potential of AOs. AAV vectors on the other hand are a powerful
tool to deliver therapeutic genes to the skeletal muscle (16)a n d
several serotypes of AAV show speciﬁc tropisms to skeletal and
cardiac muscles (17,18). The AAV serotype 9 in particular has
been reported to transduce the heart very efﬁciently (18), as
well as most of the skeletal muscles.
In this study, we investigated the therapeutic potential of sys-
temic AAV9-mediated exon skipping in a severely affected
mouse model of DMD. While the dystrophin-deﬁcient mdx
mouse has historically been used as the primary model of
DMD, the dystrophin/utrophin double-knockout (dKO) mouse
suffers from a much more severe and progressive muscle
wasting, impaired mobility and premature death (19,20).
We therefore tested the hypothesis that the AAV-
U7snRNA-mediated exon skipping we previously used in mdx
mice (11) could ameliorate the pathology associated with
severe muscular dystrophy in dKO mice. We demonstrate that
a single injection of self-complementary AAV9 vector
(scAAV9) encoding a modiﬁed U7snRNA speciﬁc to exon 23
of the dystrophin pre-mRNA induces a widespread restoration
of dystrophin expression in all muscles examined, including the
heart. This leads to a considerable improvement of the dystrophic
phenotype of these mice and a remarkable extension of lifespan.
RESULTS
Widespread dystrophin expression in dKO mice
after scAAV9-U7ex23 injection
Self-complementary AAV vectors (scAAV) have been
reported to induce higher transduction efﬁciencies than
conventional single-stranded AAV vectors (ssAAV) by cir-
cumventing the need to convert the single-stranded DNA
genome into double-stranded DNA prior to expression (21).
We therefore decided to use this type of vector for our system-
ic study in the dKO mouse model. The modiﬁed U7snRNA
speciﬁc to exon 23 of the dystrophin pre-mRNA (U7ex23)
(11) was inserted between the inverted terminal repeats
(ITRs) of a plasmid self complementary adenoviral associated
vector (pscAAV) construct, and scAAV pseudotyped with a
serotype 9 capsid were subsequently produced for optimum
skeletal and cardiac muscle delivery. dKO mice received a
single intravenous (i.v.) injection of  1E + 13 vg of
scAAV9-U7ex23 at 3 weeks of age. Control dKO mice
display a severe dystrophic phenotype from an early age
(sometimes as early as 5 weeks of age) and were sacriﬁced
at a humane endpoint which varied between 6 and 18 weeks
of age depending on the severity of their pathology (average
lifespan of 10.2 weeks). While some scAAV9-treated dKO
mice were kept for long-term analysis, six were sacriﬁced at
12 weeks of age (9 weeks after injection) for muscle analysis.
Total RNA extracted from the treated muscles was
analysed by reverse transcriptase–polymerase chain reaction
(RT–PCR) (Fig. 1A). The full-length transcript is represented
by an amplicon of 901 bp, and the in-frame transcript exclud-
ing the mutated exon 23 is represented by a 688 bp product.
The scAAV9 injection induced a very efﬁcient exon 23 skip-
ping in all skeletal muscles examined, where the skipped
product was the major product detected (Fig. 1A). Skipping
efﬁciency appeared particularly high in the heart where the
full-length transcript was hardly detectable. The shorter
542 bp amplicon corresponds to a skipped transcript lacking
exons 22 and 23 and has been reported previously (4,22).
In order to quantify more accurately the levels of exon skip-
ping in each muscle group, quantitative PCR was performed
using Taqman assays that were designed against the dystroph-
in exon 4–5 or exon 22–24 templates using the Custom Assay
Design Tool (Applied Biosystems). The percentage of exon 23
skipping was expressed as a percentage of total dystrophin as
indicated by the exon 4–5 expression level, after normaliza-
tion with an endogenous control. Exon 23 skipping levels
ranged from  20% in the diaphragm to 50% in the heart
(Fig. 1B). Despite being generally lower, the levels of exon
skipping measured by quantitative PCR (qPCR) correlated
with the nested RT–PCR results. This discrepancy was some-
what expected as it has previously been demonstrated that
nested RT–PCR may lead to overestimation of exon-skipping
levels (23).
Western blotting was performed on samples from treated
dKO mice to evaluate the restoration of dystrophin protein.
Results presented in Figure 1C and D conﬁrmed the RT–
PCR data as dystrophin expression was detected in all
muscles examined. Quantiﬁcation of the observed bands
revealed levels of dystrophin restoration between 45 and
95% of wild-type levels (Fig. 1D). Of particular signiﬁcance
was the cardiac muscle, where dystrophin rescue was almost
complete, reﬂecting the favourable tropism of the AAV sero-
type 9 for the heart.
Immunoﬂuorescence performed on tissue sections con-
ﬁrmed restoration of dystrophin and its correct localization
at the membrane of the sarcolemma in all muscles analysed
2560 Human Molecular Genetics, 2012, Vol. 21, No. 11(Fig. 2). Widespread expression of dystrophin protein over
multiple sections within each muscle group was detected in
the forelimb (biceps and triceps), hind limb [tibialis anterior
(TA)—as illustrated in Supplementary Material, Fig. S1,
gastroc and quadriceps] and diaphragm muscles. As predicted
by RT–PCR and western blot results, the level of dystrophin
expression was particularly high in the cardiac muscle which
was almost undistinguishable from the normal C57BL6 heart.
A small group of dKO mice were also injected with a
limited dose of scAAV9-U7ex23 (between 1 and 2 E + 12
vg), which induced only low levels of exon 23 skipping and
dystrophin restoration (Supplementary Material, Fig. S2).
These levels of dystrophin expression ( 10–15% in most
muscles, except in the heart where levels are high) were not
sufﬁcient to signiﬁcantly improve the dKO phenotype, sug-
gesting a threshold of vector genomes necessary to restore ad-
equate levels of dystrophin in the severe dKO model.
scAAV9-U7ex23 injection averts the onset of dystrophic
pathology in the dKO mice
In order to evaluate the functional correction induced by
exon-skipping, we ﬁrst assessed the histopathology of the
treated muscles. Histologically, dKO muscles are character-
ized by large inﬂammatory inﬁltrates and a high percentage
of centrally nucleated myoﬁbres, which reﬂect the continuous
degeneration–regeneration process. Haematoxylin and eosin
staining revealed a signiﬁcant improvement of the muscle
histopathology after exon-skipping treatment (Fig. 3A).
sc-AAV9-treated muscles displayed noticeably fewer inﬁltrat-
ing mononuclear cells as well as a drastic reduction in the per-
centage of centrally nucleated myoﬁbres ( 28%) when
compared with age-matched untreated dKO mice ( 89%)
(Fig. 3B). In addition, while dKO muscles showed an
increased number of small ﬁbres as a result of the degener-
ation–regeneration cycles, treated muscles revealed a uni-
formity of the muscle ﬁbres similar to that observed in the
C57BL6 controls, reﬂecting the functionality of the restored
dystrophin (Fig. 3A).
Next, we evaluated the restoration of the dystrophin-
associated protein complex (DAPC). Dystrophin and the
DAPC play a major structural role in muscles by forming a
link between the internal cytoskeleton actin and the extracel-
lular matrix, but the DAPC also has important signalling
functions via other components (24,25). In the absence of
functional dystrophin protein, the DAPC fails to localize cor-
rectly at the sarcolemma and its function is therefore compro-
mised. Staining of muscles sections from scAAV9-treated
dKO mice revealed the expression of the DAPC component
proteins including a-sarcoglycan, b-sarcoglycan and
b-dystroglycan and, more importantly, their correct localiza-
tion at the sarcolemma (Fig. 3C).
scAAV9-U7ex23 injection improves muscle function
and remarkably extends lifespan of dKO mice
Encouraged by the widespread restoration of dystrophin ex-
pression and the improvement of the muscle histopathology
following the scAAV9-U7ex23 injection, we investigated in
more detail the function and contractile properties of the
treated muscles. We ﬁrst assessed the forelimb muscle
strength of the treated and control mice using a functional
test of grip force strength (26,27). As expected, untreated
dKO mice displayed a reduced grip strength compared with
Figure 1. Exon-skipping and dystrophin expression in tissues from dKO mice following one i.v. injection of scAAV9-U7ex23. (A) RT–PCR analysis to detect
exon 23 skipping efﬁciency at the RNA level. The 901 bp product represents the full-length transcript, and the products of 688 and 542 bp represent transcripts
that exclude exon 23 and exons 22 and 23, respectively. (B) Quantiﬁcation of exon 23 skipping measured by Taqman qPCR. Exon 23 skipping is expressed as a
percentage of total dystrophin, measured by the exon 4–5 expression level, after normalization with an endogenous control (n ¼ 6). (C) Western blot to detect
dystrophin expression in tissues from scAAV9-treated dKO mice, compared with C57BL6 control mice (top gel). Equal loading of 100 mg protein is shown for
each sample with a-actinin expression detected as a loading control except for the C57BL6 samples for which only 50 mg was loaded (bottom gel). (D) Quan-
tiﬁcation of levels of dystrophin protein restored in various muscles. Membranes were converted to numerical pictures by scanning, and band intensities were
analysed using the ImageJ 1.33a software. Dystrophin levels are expressed as percentage compared with levels in wild-type tissue.
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scAAV9-treated dKO on the other hand showed a signiﬁcant
improvement of their grip strength, comparable to that of the
normal controls. We next investigated force production in
hind limb muscles of treated and control mice using the exten-
sor digitorum longus (EDL) muscle. As a result of the severe
muscle degeneration in dKO mice, speciﬁc force appeared
reduced in untreated dKO mice compared with C57BL6 con-
trols (Fig. 4B). scAAV9-U7ex23 treatment considerably
improved dKO muscle function such that speciﬁc force was
no longer signiﬁcantly different from that generated by wild-
type mice (Fig. 4B).
Figure 2. Dystrophin restoration in treated dKO muscles. Immunostaining of muscle tissue cross-sections to detect dystrophin expression and localization in
C57BL6 normal control mice (left panel), untreated dKO mice (middle panel) and scAAV9-U7ex23-treated mice (right panel). Tissues analysed were from
TA, gastrocnemius, quadriceps, biceps, diaphragm and heart muscles (scale bar ¼ 100 mm).
2562 Human Molecular Genetics, 2012, Vol. 21, No. 11In addition, we tested the ability of the restored dystrophin
to protect dKO myoﬁbres from exercise-induced damage, by
assessing maintenance of force production following a series
of eccentric contractions. The protocol applied resulted in a re-
duction in initial muscle contractile force of  46% in untreat-
ed dKO mice compared with only  14% in C57Bl6 mice
(Fig. 4C). Treated dKO muscles appeared somewhat protected
from contraction-induced injury as the percentage of force
drop was reduced to  30%. Taken together, these results in-
dicate that the widespread restoration of dystrophin expression
induced by the scAAV9-U7ex23-mediated exon skipping
greatly improves muscle function in the severely affected
dKO mice.
In contrast to mdx mice, dKO mice display a very severe
dystrophic phenotype, including abnormal waddling gait, con-
tracted and stiff limbs, and very pronounced kyphosis as a
Figure 3. scAAV-U7ex23 treatment improves muscle histopathology in dKO mice. (A) The left panel shows immunoﬂuorescent staining for dystrophin (green)
of tibialis anterior cross-sections from C57BL6 normal control mice (up), untreated dKO mice (middle) and peptide conjugated PMO treated mice (bottom). The
lower panel shows haematoxylin and eosin staining of the same muscles. (B) Percentage of myoﬁbres with centronucleation (n ¼ 600–1800 myoﬁbres/cohort).
∗∗∗P , 0.001 when compared with untreated dKO mice. (C) Expression of dystrophin restores the DAPC to the sarcolemma in the scAAV9-treated dKO mice.
DAPC components a- and b-sarcoglycan and b-dystroglycan were detected by immunostaining in tissue cross-section of TA muscles from scAAV9-treated dKO
mice (lower panel), compared with C57BL6 normal mice (upper panel) and untreated dKO mice (middle panel) (scale bar ¼ 100 mm).
Figure 4. Improvement of muscle function in scAAV9-treated mice. (A) Forelimb muscle function assessment shows the physical improvement of scAAV-
treated dKO mice compared with untreated dKO mice and C57BL6 normal control mice (n ¼ 6 per cohort). ∗∗∗P , 0.005 compared with untreated dKO
mice. (B) EDL muscles of scAAV-treated dKO mice were analysed for their maximal force (peak force) producing capacity compared with untreated dKO
mice and C57BL6 control mice. Maximal force was also normalized for cross-sectional area to assess speciﬁc force. ∗∗∗P , 0.005 compared with untreated
dKO mice. Speciﬁc force is not signiﬁcantly different between treated dKO and C57Bl6 (P . 0.09). (C) The percentage of force drop is assessed by measuring
the force deﬁcit following a series of ﬁve eccentric contractions. ∗P , 0.05 compared with untreated dKO mice. Error bars are shown as mean+SEM (n ¼ 6 per
cohort).
Human Molecular Genetics, 2012, Vol. 21, No. 11 2563result of the degenerative process (Fig. 5A). The reduced mus-
culature considerably affects the mobility of the mice, espe-
cially during the last few weeks of life. Supplementary
Material, Video S1, illustrates this seriously decreased ambu-
lation in a 12-week-old control dKO mouse. This severe and
progressive muscle wasting leads to premature death of the
dKO mice between 6 and 18 weeks of age depending on the
severity of their pathology (an average lifespan of 10.2
weeks; Fig. 5B and C).
The appearance and behaviour of scAAV9-treated dKO
mice was strikingly different as demonstrated in Figure 5A
and Supplementary Material, Video S2, in which the contrast
between untreated control and treated dKO mice is clearly ob-
servable. The dystrophic pathology of treated mice appeared
greatly improved as the animals demonstrated only a
minimal kyphosis and contracted limbs (Fig. 5A). Further-
more, their mobility, their food-seeking behaviour and the
turgor of the tail were markedly improved and appeared
close to normal.
In order to measure more accurately the improvement of the
dystrophic pathology in treated dKO mice, mice were moni-
tored using open-ﬁeld behavioural activity cages (28).
scAAV9-U7ex23-treated dKO mice show signiﬁcant improve-
ment compared with age-matched untreated controls for most
of the recorded parameters, 12 of which are shown in
Figure 6A. Total activity, active time, rearing time and dis-
tance travelled, which are considered some of the best para-
meters for activity monitoring, are also represented as
graphs in Figure 6B. Treated mice were shown to be signiﬁ-
cantly more active, travel further and rear more than the un-
treated controls, conﬁrming the impressive improvement of
their dystrophic pathology following a single injection of
scAAV9-U7ex23.
While six scAAV9-treated dKO mice were sacriﬁced at 12
weeks of age for muscle analysis, six others were kept for
long-term analysis to investigate the effect of exon skipping
on lifespan. Remarkably, treated dKO mice still appeared
healthy and active when older as illustrated in Supplementary
Material, Video S3, of an 11-month-old-treated dKO mouse,
reﬂecting the long-term effect of AAV vectors.
dKO mice treated with a single injection of
scAAV9-U7ex23 at 3 weeks of age survived for  1 year
(an average lifespan of 50.2 weeks, n ¼ 6), which represents
a considerable improvement compared with untreated dKO
mice (Fig. 5B and C). Analysis of muscles from treated
dKO mice close to the endpoint revealed that exon 23 skipping
and dystrophin expression were still detected nearly 1 year
after the injection (Fig. 7), albeit levels being lower than
those observed at 12 weeks of age. Levels of skipping and dys-
trophin appeared particularly lower in some hind limb muscles
and the diaphragm, compared with the heart where dystrophin
expression was still very high, which correlated with the de-
tection of U7dtex23 transgene (Supplementary Material,
Fig. S3).
Biomarkers levels dramatically improved after
scAAV9-U7ex23 injection
Various biomarkers characteristic of muscular dystrophies,
such as levels of creatine kinase in the serum have been iden-
tiﬁed over the years and have been used as valuable tools for
the diagnosis of DMD. More recently, levels of speciﬁc
muscle microRNAs (miRNAs), released into the bloodstream
of DMD patients, have been described to correlate with the se-
verity of the disease as a consequence of ﬁbre damage (29).
The same miRNAs have also been shown to be abundant in
the blood of mdx mice and recover to wild-type levels in
animals rescued through AO-mediated exon skipping (29).
We therefore wanted to investigate the levels of these
miRNAs in our scAAV-treated dKO mice compared with un-
treated dKO and healthy controls. Since these biomarkers can
be analysed from the serum, they represent ideal tools to
monitor the outcomes of therapeutic interventions, especially
in our older scAAV9-treated dKO mice without the need to
Figure 5. scAAV9-U7ex23 treatment averts the onset of dystrophic pathology in the dKO mice. (A) Photograph of an untreated dKO mouse at 12 weeks of age
(left), displaying a strong kyphosis and joint contractures compared with an scAAV9-U7ex23-treated mouse at 24 weeks of age (right), looking healthy. (B)
Average lifespan of untreated dKO and scAAV9-U7ex23-treated dKO mice. (C) Survival curves of untreated dKO (dash line) and scAAV9-U7ex23-treated
dKO mice (continuous line).
2564 Human Molecular Genetics, 2012, Vol. 21, No. 11sacriﬁce them. Total RNA was extracted from blood serum
from 40-week-old-treated dKO mice and qPCR was utilized
to calculate the relative expression of miR-1 and miR-206 in
untreated and treated mice to healthy controls. miR-223 ex-
pression was used as an endogenous control for DDCt analysis
as described previously (29). As expected, dKO mice dis-
played much higher levels of miR-1 and miR-206 in the
blood compared with wild-type controls (Fig. 8A and B).
scAAV9-treated dKO mice on the other hand showed a re-
markable reduction in the levels of miR-1 and miR-206,
reﬂecting the beneﬁt of the exon-skipping treatment.
We also demonstrated that treated dKO mice displayed a
massive reduction in serum creatine kinase levels when com-
pared with untreated dKO mice (Fig. 8C). This signiﬁcant
drop indicates a whole-body reduction in muscle degeneration
consistent with the widespread restoration of dystrophin ex-
pression. Finally, we analysed circulating levels of aspartate
aminotransferase (AST) and alanine aminotransferase (ALT),
which are present in a variety of extrahepatic tissues, including
cardiac and skeletal muscles. In both cases, levels were signiﬁ-
cantly lower in scAAV-treated dKO mice (Fig. 8D and E), in-
dicating that restored dystrophin protein improved the
integrity of muscle sarcolemma. Analysis of all the above bio-
marker levels conﬁrms that the widespread restoration of dys-
trophin expression induced by the scAAV9-U7ex23-mediated
exon skipping greatly improves muscle function in the long
term in dKO mice.
DISCUSSION
In this study, we report the rescue of the severely affected
dKO mouse model through AAV-mediated exon skipping. A
single injection of scAAV9-U7ex23 leads to a considerable
improvement of the dystrophic phenotype and muscle function
of these mice accompanied by a remarkable extension of life-
span. Antisense-mediated exon skipping is one of the most
promising approaches for the treatment of DMD, and early
clinical trials have demonstrated encouraging results after
both local and systemic administration of AOs. However,
some substantial scientiﬁc barriers remain, especially regard-
ing the personalized medicine nature of the strategy and the
challenge of delivering to all affected tissues in DMD. The
use of AAV vectors to deliver antisense sequences can circum-
vent some of these challenges as they offer the possibility of
an efﬁcient and stable transduction of all skeletal and
cardiac muscles. While conventional AOs are still limited by
a poor cellular uptake restricted to leaky muscle ﬁbres, AAV
vectors on the other hand transduce all muscle ﬁbres equally
efﬁciently regardless of their dystrophic/leaky state. The
Figure 6. Improvement of physical activity and behaviour following scAAV9-U7ex23 injection. Mice were analysed at 10 weeks of age with open-ﬁeld behav-
ioural activity cages. (A) The 12 most relevant out of 22 recorded parameters are reported. Arrows indicate an increase ( ) or a decrease ( ) in the value of the
measured parameter for the treated dKO mice compared with untreated controls. (B) Total activity, (C) total active time, (D) rearing time and (E) distance
travelled are represented as graphs. ∗P , 0.05, ∗∗P , 0.01 and ∗∗∗P , 0.005 compared with untreated dKO mice. Error bars are shown as mean+SEM
(n ¼ 6 per cohort).
Human Molecular Genetics, 2012, Vol. 21, No. 11 2565Figure 7. Analysis of exon-skipping and dystrophin expression at an endpoint in scAAV9-U7ex23-treated dKO mice. (A) RT–PCR analysis to detect exon 23
skipping efﬁciency at the RNA level. The 901 bp product represents the full-length transcript, and the products of 688 and 542 bp represent transcripts that
exclude exon 23 and exons 22 and 23, respectively. (B) Quantiﬁcation of exon 23 skipping measured by Taqman qPCR. Exon 23 skipping is expressed as a
percentage of total dystrophin, measured by the exon 4–5 expression level, after normalization with an endogenous control. (C) Western blot to detect dystrophin
expression in tissues from scAAV9-treated dKO mice, compared with untreated dKO and C57BL6 control mice (top gel). Equal loading of 100 mg protein is
shown for each sample with a-actinin expression detected as a loading control, except for the heart and the C57BL6 control, where only 50% were loaded
(bottom gel). (D) Quantiﬁcation of levels of dystrophin protein restored in various muscles. Membranes were converted to numerical pictures by scanning,
and band intensities were analysed using the ImageJ 1.33a software. Dystrophin levels are expressed as percentage compared with levels in wild-type tissue.
Figure 8. scAAV9-U7ex23 injection leads to a decrease in circulating biomarkers levels. (A and B) dKO mice were treated with a single i.v. injection of
scAAV9-U7ex23 at 3 weeks of age, and blood serum was sampled at 40 weeks of age. Total RNA was extracted from serum and qPCR was utilized to calculate
the relative expression of miR-1 and miR-206 in untreated and treated mice to healthy controls. miR-223 expression was used as an endogenous control for DDCt
analysis as described previously (29). Data indicate the mean and standard deviation of the expression levels of a minimum of ﬁve mice for each treatment.
∗∗∗P , 0.001. (C) Measurement of serum CK levels as an index of ongoing muscle membrane instability in scAAV9-U7ex23-treated dKO mice compared
with untreated dKO mice (∗P , 0.005) and C57BL6 normal control mice. (D and E) Measurement of serum ALT and AST scAAV9-U7ex23-treated dKO
mice compared with untreated dKO mice (∗∗∗P , 0.001) and C57BL6 normal control mice.
2566 Human Molecular Genetics, 2012, Vol. 21, No. 11resulting dystrophin is more uniformly expressed within each
muscle, as we observed in scAAV9-U7ex23-injected dKO
mice. This could represent an advantage in clinical trials as
the efﬁcacy in humans will not be dependent on the number
of leaky muscle ﬁbres.
An additional challenge faced by AO-mediated exon skip-
ping for DMD at present is the very little efﬁcacy observed
in the cardiac muscle (12,15). Clinically, cardiomyopathy is
the second leading cause of death in patients with DMD in
countries where ventilator therapy has been introduced,
accounting for 10–40% of deaths in DMD populations (30),
which implies a clear need for cardiac dystrophin correction.
The reasons for the low efﬁciency of cardiac dystrophin restor-
ation using AOs are unclear, but are probably related to the
poor ability of unmodiﬁed oligonucleotides to penetrate the
heart. In this study, on the other hand, we report particularly
high levels of dystrophin expression in the heart following a
single injection of scAAV9-U7ex23. This can be explained
by the favourable tropism of the AAV serotype 9 for the
cardiac muscle as described previously (17,18). The cardiac
function was not assessed in dKO mice as we have previously
reported that restoration of diaphragm and other respiratory
muscle function was sufﬁcient to prevent cardiomyopathy in
dystrophic mice (31).
The causes of death in untreated dKO are still unclear and
likely the result of respiratory failure and/or lack of food
and water due to the severely decreased mobility towards
the end of their life. The efﬁcient restoration of dystrophin
described here in the heart of treated dKO mice may have con-
tributed to their extended lifespan. However, dKO mice can
survive over 1 year even without cardiac dystrophin restor-
ation as we demonstrated using peptide-conjugated AOs in
earlier studies (31,32). It is therefore more plausible that the
remarkable extension of dKO lifespan results from the wide-
spread restoration of dystrophin throughout the whole body
of dKO mice and especially the respiratory muscles.
Cell-penetrating peptide-conjugated AOs offer similar de-
livery advantages than AAV vectors as they have also
addressed some of the issues faced by conventional AOs,
such as efﬁcient delivery to non-leaky ﬁbres and the heart
(33–37). They could therefore represent an effective strategy
to reduce the dose level and dose frequency for clinical appli-
cation. However, the toxicity of the current peptide chemistry
poses a challenge for determination of an effective and safe
regimen in man. One of these peptides, for example, was
found to cause mild tubular degeneration in the kidneys of
cynomolgus monkeys (37). The nature of the toxicity is not
well understood, but it is likely to be due to the cationic
nature of the peptide, impairing their clinical applicability at
the current stage.
The main advantage of AAV vectors over naked or even
conjugated AOs is the stability of the gene expression
leading to a long-term restoration of dystrophin. In this
work, we show that a single injection of scAAV9-U7ex23 is
sufﬁcient to rescue the severe dKO phenotype and remarkably
extend lifespan. In order to evaluate the efﬁcacy of the
scAAV9-U7ex23 injection in the long term without sacriﬁcing
the injected mice, we investigated the levels of circulating bio-
markers. In addition to the classic creatine kinase, AST and
ALT levels, we analysed levels of miR-1 and miR-206,
which have recently been reported to correlate with the
severity of the pathology in DMD patients (29). All these bio-
markers conﬁrmed the long-term reduction in muscle degener-
ation consistent with the widespread restoration of dystrophin
expression. These miRNAs released into the bloodstream rep-
resent ideal biomarkers to monitor the outcomes of therapeutic
interventions, especially in older treated mice without the need
to sacriﬁce them. Exon 23 skipping and dystrophin expression
were still detected in treated animals 1 year after the injection,
conﬁrming the stability of AAV vectors in skeletal and cardiac
muscles. Nonetheless, levels of skipping and protein were
lower than those observed at 12 weeks of age, especially in
the diaphragm, which may not have been sufﬁcient to maintain
the older dKO mice in healthy condition. Interestingly, this
decrease in skipping and dystrophin levels correlated with
the levels of U7ex23 transgene detected in the muscles (Sup-
plementary Material, Fig. S3), indicating a loss of vector
genome over time. This was somehow expected considering
the severe and rapidly progressing pathology of dKO mice,
imposing cycles of degeneration and regeneration to the
muscles. Although the injection of scAAV9-U7ex23 induced
widespread restoration of dystrophin, protecting the treated
muscles, levels and distribution of dystrophin indicate that
not all ﬁbres were transduced or sufﬁciently rescued, allowing
the pathological degeneration process to continue. Moreover,
we must keep in mind that the exon-skipping strategy converts
transduced dystrophic ﬁbres into BMD-like ﬁbres, which are
known to be less resilient than normal ones as observed in
very mild BMD patients.
We also noticed that the rescue of dKO mice required a
minimal dose of 5E + 12 vg of scAAV9-U7ex23 injected,
suggesting a threshold of dystrophin restoration necessary
for the dKO survival. The few dKO mice injected with less
than 5E + 12 vg displayed very low levels of dystrophin ex-
pression and only showed a very slight improvement of their
phenotype and lifespan. While these observations might be
concerning by suggesting the need of high doses of AAV
vectors for translation, this may be explained by the early
onset of dystrophy in these mice and the rapid and progressive
nature of their pathology, which requires particularly high
levels of dystrophin restoration. This requirement, which we
had previously observed in our earlier study using peptide-
conjugated AOs in dKO mice, suggests that the dKO model
might not be appropriate for evaluating low-dose regimens
(32). However, the comparatively longer time scale of
disease progression in DMD patients might allow slow accu-
mulation and restoration of dystrophin through low-dose treat-
ment, which could be clinically applicable.
Although the use of AAV vectors offers many advantages
such as long-term and widespread restoration of dystrophin
as discussed above, they still face immunological challenges.
Results from recent studies in larger animal models and in
early human trials highlight immunological complications
associated with viral vector-mediated gene transfer as the
major barrier to clinical success. While AAV vectors do not
elicit a cellular immune response in mice, multiple labs have
now observed that AAVs 1, 2, 6 and 8 can elicit an immune
response in the dog model for DMD (38–41), in monkeys
(42) and in humans (43–47). However, studies in dystrophic
dogs also showed that this T-cell response could be blocked
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applied with success in non-human primates (42,49).
There is also some concern that dystrophin itself may be im-
munogenic in dystrophin-deﬁcient patients. In the human trial
of dystrophin gene transfer by Mendell et al. (50), intramuscu-
lar injections of rAAV2-minidystrophin resulted in robust
mini-dystrophin-speciﬁc T-cell activity and none of the six
patients injected displayed any detectable exogenous dys-
trophin. The authors proposed that dystrophin epitopes from
revertant dystrophin ﬁbres could prime the T-cell response.
However, recent clinical trials evaluating AO-mediated exon
skipping have not reported any immune response against the
restored dystrophin (5–8), suggesting that restoration of dys-
trophin expression following intramuscular or systemic deliv-
ery will not necessarily trigger an immune response. Differing
from a conventional gene therapy approach where the trans-
gene expression is driven by a ubiquitous promoter, the
AAV-U7snRNA system induces dystrophin expression only
in cells naturally expressing it, which reduces the chances of
activating the immune response through transduction of
antigen-presenting cells. The AAV-U7snRNA approach may
therefore circumvent this T-cell activation and represents the
best of both worlds, combining the efﬁcacy of a viral gene
transfer system with the speciﬁcity of the exon-skipping
strategy.
The use of viral vectors to shuttle antisense sequences also
offers the possibility of delivering several U7snRNAs with the
same vehicle, which could therefore target multiple exons.
The number of DMD patients eligible for therapeutic exon
skipping dramatically increases when considering double and
multiexon skipping, reaching up to 83% of all DMD muta-
tions. Of particular interest, the multiskipping of exons 45–
55 in the hot-spot mutation region would be applicable to
63% of the patients and would also create a deletion associated
with a mild phenotype (51). While double and multiexon skip-
ping can be challenging using AOs (52), viral vectors can
deliver different antisense constructs to the same nucleus,
making the viral approach much more appealing to achieve
multiexon skipping (53).
In conclusion, we report here a remarkable rescue of the
dystrophic pathology in the severely affected dKO mice fol-
lowing a single injection of scAAV9-U7ex23. The improve-
ment of the dKO phenotype and muscle function were not
only demonstrated by electrophysiology on isolated muscle
or observation of the mice (photos and videos), but also mea-
sured using open-ﬁeld activity monitoring. This work repre-
sents an important milestone for the clinical application of
the AAV-U7snRNA-mediated exon skipping approach,
which is currently being planned for 2013.
MATERIALS AND METHODS
Viral vector production
For AAV vector production, the U7ex23 fragment was
introduced between the ITR of a pscAAV construct for sub-
sequent production of self-complementary vector. scAAV9-
pseudotyped vectors were prepared by co-transfection in 293
cells of scAAV-U7ex23, pXX6 encoding adenovirus helper
functions and pAAV9pITRCO2 that contains the AAV9 rep
and cap genes. Vector particles were puriﬁed on Iodixanol gra-
dients from cell lysates obtained 48 h after transfection and
titres were measured by quantitative real-time PCR (54).
scAAV9-U7ex23 injections and animal experiments
dKO mice are generated by crossing (utr+/2, dys2/2) mice,
which have been obtained by crossing the utr2/2 mice
(C57Bl6) with mdx mice (20). Approximately 1E + 13 vg of
scAAV9-U7ex23 was delivered to dKO mice at 3 weeks of
age, by i.v. injection in the tail vein with mice under general
anaesthesia. Treated mice were killed at 13 weeks of age or
at a humane endpoint by CO2 inhalation. Muscles were snap-
frozen in liquid nitrogen-cooled isopentane and stored at
2808C before further analysis. All animal experiments were
carried out in Biomedical Science Building, University of
Oxford, Oxford, UK, and performed according to the guide-
lines and protocols approved by the Home Ofﬁce.
Open-ﬁeld activity monitoring
The Linton AM1053 X, Y, Z IR Activity Monitors were used
for open-ﬁeld activity monitoring. Mice were acclimatized in
empty cages for 90 min the day prior to actual data collection.
The data were collected every 10 min over a 90 min period for
3 consecutive days. The ﬁrst three of the nine recordings each
day were disregarded upon analysis. Twenty-two different ac-
tivity parameters were measured for each mouse, with total
distance travelled, total activity, rearing time and total
mobile counts considered the best parameters for monitoring
behavioural activity.
Immunohistochemistry and histology
Sections of 8 mm were cut from at least two-thirds of the
muscle length of the TA, gastrocnemius, quadriceps, glutaeus,
biceps, triceps, diaphragm and cardiac muscle at 100 mm
intervals. The intervening muscle sections were collected for
subsequent RT–PCR analysis. Routine haematoxylin and
eosin staining was used to examine the overall muscle
morphology. The cryosections were then examined for dys-
trophin expression using the mouse monoclonal antibody
NCL-DYS2 (Novocastra, UK). DAPC protein detection was
also performed using mouse monoclonal antibodies to
b-dystroglycan and a- and b-sarcoglycan according to the
manufacturer’s instructions (Novocastra). The polyclonal anti-
body was detected by goat-anti-rabbit IgGs Alexa 488 and the
monoclonal antibodies were used with an M.O.M. kit (Vector
Laboratories, Burlingame, CA, USA).
RNA isolation and RT–PCR analysis
Total RNA was isolated from intervening muscle sections col-
lected during cryosection using TRIzol reagent according to
the manufacturer’s instructions (Invitrogen, UK). Aliquots of
200 ng of total RNA were used for RT–PCR analysis using
the Access RT–PCR System (Promega) in a 50 ml reaction
using the external primers Ex 20Fo (5′-CAGAATTCTG
CCAATTGCTGAG-3′) and Ex 26Ro (5′-TTCTTCAGCTTGT
GTCATCC-3′). The cDNA synthesis was carried out at 458C
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of 948C (30 s), 588C (1 min) and 728C (2 min). Two microli-
tres of these reactions were then reampliﬁed in nested PCRs by
22 cycles of 948C (30 s), 588C (1 min) and 728C (2 min) using
the internal primers Ex 20Fi (5′-CCCAGTCTACCACCC
TATCAGAGC-3′) and Ex 26Ri (5′-CCTGCCTTTAAGGCTT
CCTT-3′). PCR products were analysed on 2% agarose gels.
Quantitation of exon 23 skipping by quantitative PCR
RNA was isolated from mouse tissue as described above. Con-
taminating DNA was removed from the RNA preparations
using the Turbo DNA-free system (Ambion). One-microgram
aliquots of DNase-treated RNA were then subjected to reverse
transcription using the First Strand synthesis system (Invitro-
gen) with random hexamers according to the manufacturer’s
instructions. qPCR was performed using Taqman assays that
were designed against the exon 4–5 or exon 22–24 templates
using the Custom Assay Design Tool (Applied Biosystems,
primer/probe sequences available upon request). An inventor-
ied 18S assay was utilized as an endogenous control (Applied
Biosystems, 4310893E). Fifty nanograms of cDNA were used
as an input per reaction and all assays were carried out in sin-
gleplex. Assays were performed under fast cycling conditions
on an Applied Biosystems StepOne Plus thermocycler, and all
data were analysed using the comparative Ct method using the
associated StepOne analytical software. For a given sample,
the delta-Ct values of exon 4–5 and exon 22–24 assays
were used to calculate a relative abundance of total dystrophin
and exon 23-skipped dystrophin mRNA, respectively. Exon 23
skipping was then expressed as a percentage against total dys-
trophin, as indicated by the exon 4–5 expression level.
Western blot analysis
Total protein was extracted from muscle samples with New-
castle buffer (3.8% sodium dodecyl sulphate, 75 mM Tris–
HCl, pH 6.7, 4 M urea, 10% b-mercaptoethanol, 10% glycerol
and 0.001% bromophenol blue) and quantiﬁed using the
bicinchoninic acid protein assay kit, according to the manufac-
turer’s instructions (Perbio Science, UK). Samples were dena-
tured at 958C for 5 min before 100 mg of protein was loaded in
a 5% polyacrylamide gel with a 4% stacking gel. Gels were
electrophoresed for 4–5 h at 100 V and blotted to a polyviny-
lidene diﬂuoride membrane overnight at 50 V. Blots were
blocked for 1 h with 10% non-fat milk in phosphate-buffered
saline–Tween buffer. Dystrophin and a-actinin proteins were
detected by probing the membrane with 1:100 dilution of
NCL-DYS1 primary antibody (monoclonal antibody to dys-
trophin R8 repeat; Novocastra) and 1:200 dilution of
a-actinin primary antibody (Santa Cruz Biotechnology), re-
spectively. An incubation with a mouse horseradish
peroxidase-conjugated secondary antibody (1:2000) or goat
horseradish peroxidase-conjugated secondary antibody
(1:160000) allowed visualization using ECL Analysis
System (GE Healthcare). Membranes were converted to nu-
merical pictures by scanning, and band intensities were ana-
lysed using the ImageJ 1.33a software (http://rsb.info.nih.
gov/ij/).
Muscle function analysis
Functional grip strength analysis was performed on treated and
control mice at 12 weeks of age using a commercial grip
strength monitor (Chatillon, UK). Each mouse was held
2 cm from the base of the tail, allowed to grip a bar attached
to the apparatus with their fore paws and pulled gently until
they released their grip. The force exerted was recorded
from four sequential tests, averaged at 1 min apart. Speciﬁc
force and force drop were measured from the EDL muscle
dissected from the hind leg of the treated and control mice.
During dissection and experiments, muscles were bathed in
oxygenated (95% O2–5% CO2) Krebs–Hensley solution
composing of (mM): NaCl, 118; NaHCO3, 24.8, KCl, 4.75;
KH2PO4, 1.18; MgSO4, 1.18; CaCl2, 2.54; and glucose, 10.
Contractile properties were measured as described
previously (32).
Biomarker level quantiﬁcation from the serum
Blood samples were collected from tail bleeds under general
anaesthesia. Analysis of serum creatine kinase (CK), ALT
and AST levels was performed by the pathology laboratory
(Mary Lyon Centre, Medical Research Council, Harwell, Ox-
fordshire, UK). Extraction and quantitation of miRNAs from
serum: total RNA was extracted 25 ml aliquots of erythrocyte-
free serum using Trizol LS (Invitrogen) according to the man-
ufacturer’s instructions, except that the RNA pellet was
washed with 80% ethanol instead of 70%. Ten nanograms of
total RNA of each sample to be analysed were then used as
an input for reverse transcription using the microRNA
Reverse Transcription Kit (Applied Biosystems) according to
the manufacturer’s instructions. Individual reverse transcrip-
tion reactions were performed in the presence of a single
miRNA-speciﬁc primer supplied with the corresponding
TaqMan assay (Applied Biosystems), and each RNA sample
was subjected to reverse transcription reactions for each of
the miRNAs to be studied. Inventoried miRNA TaqMan
qPCR assays were obtained from Applied Biosystems
(Assay IDs: hsa-miR-1, hsa-miR-203, hsa-miR-223). qPCR
was performed on the cDNA using an Applied Biosystems
StepOne Plus thermocycler. All miRNA data were subjected
to DDCt analysis using miR-223 expression levels as an
endogenous control. For each of miR-1 and miR-206, expres-
sion levels in dKO and scAAV-treated mice were expressed
relative to the mean expression of ﬁve healthy C57 control
mice. Student’s t-test analysis (two-tailed, unequal variance)
was performed between the mean levels of relative miRNA ex-
pression of ﬁve untreated (dKO) and six treated (scAAV) mice.
Statistical analysis
All results are expressed as mean values+SEM, unless other-
wise stated. Differences between treated and control cohorts
were determined using an unpaired Student’s t-test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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